Richard Bartram

CFO at MBX Biosciences

Richard Bartram has more than 15 years of finance and accounting experience. Mr. Bartram is our Chief Financial Officer.

Prior to joining MBX, Mr. Bartram served as Chief Financial Officer at Esperion Therapeutics, Inc. a publicly traded pharmaceutical company focused on the development and commercialization of therapies for patients with elevated LDL-C cholesterol. During his time at Esperion, Mr. Bartram led the completion of several equity and non-equity financings, aggregating to more than $1.2 billion in proceeds, and provided key contributions to business development license transactions and the approval and commercialization of Esperion’s first products, Nexletol® and Nexlizet®. Prior to Esperion, Mr. Bartram served as a public accountant at PricewaterhouseCoopers, LLP in its Assurance practice. Mr. Bartram earned both a Master of Science in Accounting and a Bachelor of Arts in Accounting from Michigan State University and is a licensed Certified Public Accountant in the state of Michigan.

Timeline

  • CFO

    Current role